GOLGA6L1

Across TCGA pan-cancer cohorts, GOLGA6L1 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated GOLGA6L1 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GOLGA6L1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6L1 expression acts as an unfavorable survival marker, although some lineages such as SCLC and ESCA show a favorable association.

STAD, UCS, and KIRP are the cancer types where GOLGA6L1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	IV	0.113	0.570	<.001	66	view →
UCS	OS	Tertile	All	0.169	0.593	.002	54	view →
KIRP	OS	Tertile	All	0.455	0.907	<.001	45	view →
LUAD	OS	Tertile	III,IV	0.305	0.673	.024	39	view →
KIRC	DFS	Tertile	III,IV	0.217	0.743	.013	36	view →
UCEC	DFS	Tertile	III,IV	0.247	0.596	.037	30	view →
SCLC	OS	Quartile	All	0.787	0.635	.011	21	view →
SARC	OS	Tertile	All	0.109	0.827	<.001	18	view →
COAD	OS	Tertile	IV	0.140	0.657	.035	9	view →
ESCA	DFS	Median	II,III,IV	1.000	0.465	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

GOLGA6L1–STAD (OS)

Open the STAD breakdown →